It is a pivotal time in the cell-based immuno-oncology field. Following the first generation of success in cell therapy – the use of stem cell transplantation in cancer – comes the next evolution in cancer treatment with chimeric antigen receptor T-cell (CAR-T) therapy. These statements echo the sentiments heard at the Alliance for Regenerative Medicine's (ARM’s) 2017 Annual Cell & Gene Investor Day on April 27 in Boston. Informa Pharma Intelligence's Datamonitor Healthcare was in attendance and reported back some of the key highlights.
"This is the beginning of a new field," commented David Epstein, an executive partner at Flagship Pioneering (formerly Flagship Ventures)....